Loading institutional data...
Loading institutional data...
Held by 232 of 5,944 reporting institutions (93th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$44M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -17%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $68M covers all $29M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2022-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~9.9% on $203M of debt.
Cash vs short-term debt unavailable.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $407.3M 100.0% | $333.6M 100.0% | $124.5M 100.0% | $52.2M 100.0% | $10.1M 100.0% | $7.6M 100.0% | $5.3M 100.0% | $2.6M 100.0% | $42.0M 100.0% | — |
| Cost of Revenue | $39.5M 9.7% | $50.6M 15.2% | $17.8M 14.3% | $4.1M 7.9% | $1.0M 9.9% | $145K 1.9% | $600K 11.4% | $466K 17.9% | $8.4M 20.0% | — |
| Gross Profit | — | — | — | — | — | — | $4.7M 88.6% | $2.1M 82.1% | $33.6M 80.0% | — |
| Research & Development | $71.5M 17.6% | $52.3M 15.7% | $35.5M 28.6% | $35.2M 67.5% | $91.1M 902.6% | $65.1M 859.2% | $71.7M 1357.3% | $69.4M 2661.0% | $75.5M 179.7% | $94.2M |
| Selling, General & Admin | $337.2M 82.8% | $258.7M 77.5% | $134.4M 108.0% | $76.6M 146.9% | $72.3M 716.1% | $33.2M 437.9% | $24.3M 459.5% | $23.7M 909.7% | $23.2M 55.3% | $18.7M |
| Total Operating Expenses | $448.3M 110.1% | $361.6M 108.4% | $187.7M 150.8% | $111.8M 214.3% | $163.4M 1618.7% | $98.4M 1299.0% | $95.9M 1816.8% | $93.1M 3570.7% | $98.7M 235.0% | $112.9M |
| Operating Income | -$41.0M -10.1% | -$27.9M -8.4% | -$63.3M -50.8% | -$63.8M -122.2% | -$154.3M -1528.6% | -$90.8M -1199.0% | -$91.3M -1728.1% | -$90.9M -3488.6% | -$65.1M -155.0% | -$112.9M |
| Interest Expense | $20.1M 4.9% | $13.0M 3.9% | $5.0M 4.0% | $3.4M 6.5% | $4.5M 44.6% | $5.1M 67.3% | $5.7M 108.4% | $3.5M 135.6% | — | — |
| Other Income (Expense), net | $8.7M 2.1% | $9.2M 2.7% | $6.6M 5.3% | $1.6M 3.1% | $687K 6.8% | $1.6M 20.7% | $2.4M 44.5% | $3.2M 122.2% | $2.0M 4.7% | $508K |
| Pretax Income | -$60.6M -14.9% | -$38.9M -11.7% | -$65.5M -52.6% | -$67.2M -128.8% | -$158.2M -1566.4% | -$94.3M -1245.7% | -$94.6M -1792.0% | -$91.3M -3501.9% | -$63.2M -150.4% | -$112.4M |
| Income Tax Expense | $969K 0.2% | $266K 0.1% | $547K 0.4% | $8K 0.0% | $4K 0.0% | $2K 0.0% | $303K 5.7% | $4K 0.2% | $1.2M 2.8% | — |
| Net Income | -$62.0M -15.2% | -$39.0M -11.7% | -$66.0M -53.0% | -$67.0M -128.5% | -$158.0M -1564.8% | -$94.3M -1245.7% | -$94.9M -1797.8% | -$91.3M -3502.0% | -$64.3M -153.2% | -$112.4M |
| Per Share | ||||||||||
| EPS (Basic) | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 | $-1.05 | $-1.47 | — | — | — |
| EPS (Diluted) | $-0.26 | $-0.17 | $-0.30 | $-0.42 | $-1.52 | $-1.05 | $-1.47 | — | — | — |
| Weighted Avg Shares (Basic) | 241.0M | 235.2M | 219.3M | 158.7M | 104.2M | 89.6M | 64.5M | — | — | — |
| Weighted Avg Shares (Diluted) | 241.0M | 235.2M | 219.3M | 158.7M | 104.2M | 89.6M | 64.5M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| ARDX | $826M | — | — | 2.0× | 22.1% | 90.3% | -15.1% | -36.9% | -16.7% | -5.3× | 232 |
Peers = companies sharing ARDX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-09-17
Where each multiple sits in its own 12-yr range · 29th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 12-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.1× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 17.9 | 11.4 | 1.9 | 9.9 | 7.9 | 14.3 | 15.2 | 9.7 |
| Gross Profit | 82.1 | 88.6 | — | — | — | — | — | — |
| R&D | 2661.0 | 1357.3 | 859.2 | 902.6 | 67.5 | 28.6 | 15.7 | 17.6 |
| SG&A | 909.7 | 459.5 | 437.9 | 716.1 | 146.9 | 108.0 | 77.5 | 82.8 |
| Operating Income | -3488.6 | -1728.1 | -1199.0 | -1528.6 | -122.2 | -50.8 | -8.4 | -10.1 |
| Income Tax | 0.2 | 5.7 | 0.0 | 0.0 | 0.0 | 0.4 | 0.1 | 0.2 |
| Net Income | -3502.0 | -1797.8 | -1245.7 | -1564.8 | -128.5 | -53.0 | -11.7 | -15.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ARDX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.